Psychedelic Science Research,
what lands in your inbox each week:
- ๐7 fresh studies
- ๐plain-language summaries
- โ direct links to original studies
- ๐ top journal indicators
- ๐ weekly delivery
- ๐งโโ๏ธalways free
some of our latest newsletters:
(select one to read it below)
Psilocybin reduces specific brain cells' activity while boosting others
This week brought fresh insights into how psychedelics reshape the brain, from the cellular circuits they target to their potential for treating everything from depression to Alzheimer's. Here's what researchers discovered about these mind-altering compounds.
๐ง Psilocybin rewires brain inhibition by targeting specific cell types
Psilocybin reduces firing in somatostatin-expressing interneurons while increasing activity in parvalbumin-expressing interneurons in mouse brains
The drug acts specifically on 5-HT1A receptors in SST interneurons, contributing to its long-term behavioral effects
This cell type-specific response reshapes cortical inhibition in ways that may explain psilocybin's therapeutic effects
Why it matters: Understanding exactly which brain cells psilocybin targets could help researchers design more precise psychedelic therapies with fewer side effects.
Key Findings
๐ฌ Group psilocybin therapy helps cancer patients after initial partial response
13 cancer patients with metastatic disease received a second round of group retreat psilocybin therapy after partial response to initial treatment
Depression scores dropped from 15.08 to 9.00 within 8 days and remained low at 24 weeks, with 69% achieving scores below clinical thresholds
77% experienced complete mystical experiences in the second session (up from 38% initially) using higher doses and optional boosters
๐ Ketamine shows faster antidepressant effects in bipolar vs unipolar depression
97 adults with treatment-resistant depression received intravenous ketamine in a naturalistic clinical setting
Patients with bipolar depression showed faster and greater improvement than those with unipolar depression, with differences emerging at week 2 and lasting through 3 months
Both groups experienced significant symptom reductions, but bipolar patients had superior and more sustained responses
๐งฌ New ketamine mechanism discovered through receptor cross-talk
Ketamine's antidepressant action depends on interaction between TrkB and mGluR5 receptors in the brain
mGluR5 amplifies brain-derived neurotrophic factor signaling while BDNF drives mGluR5 removal from synapses
An mGluR5 enhancer can boost ketamine's effects, suggesting potential combination therapies
๐ฏ Ketamine's anti-suicide effects resist treatment resistance severity
154 adults with treatment-resistant depression received ketamine in controlled trials with symptom-specific analysis
Anti-suicidal effects remained robust across all levels of treatment resistance
Improvements in sadness and anxiety were diminished in patients with higher resistance scores
๐งช 2C-B produces psychedelic effects similar to MDMA and psilocybin
24 healthy participants received 2C-B (10, 20, 30mg), MDMA (125mg), or psilocybin (25mg) in controlled trials
30mg 2C-B induced comparable drug effects to MDMA and increased emotional empathy similarly
2C-B had shorter duration (4.9 hours vs 6.1 for psilocybin) and caused less cardiovascular stimulation than MDMA
๐ Magic mushrooms may have evolved to deter insects, not attract them
Fruit fly larvae exposed to psilocybin-containing mushroom extracts showed reduced survival and pupation rates
Adults exposed during development had smaller thorax and wing size with developmental stress indicators
DNA analysis revealed distinct invertebrate communities around psilocybin mushrooms compared to non-psychedelic species
Implications
These studies reveal psychedelics work through surprisingly specific cellular and molecular mechanisms, from targeting distinct brain cell types to enabling receptor cross-talk. The findings suggest more personalized approaches to psychedelic therapy may be possible, with different compounds and protocols optimized for specific conditions and patient characteristics.
Science is the only real news.
The rest is just drama ๐ฐ
And nowadays, we see that drama everywhere.
Drama sells ads, ads sell products, and my attention sells to the highest bidder.
Drama media is junk food for the mind.
A quick rush, hard to avoid, but little nutritional value.
The brain wants broccoli ๐ง ๐ฅฆ
And look, it's not that science never makes the news.
But think about when it doesโdoes the news really understand the science it reports on?
Like it or not, AI exists now.
And it happens to be a huge science nerdโฆ ๐ญ๐ค
โฆwith a superpowerโฆ
...unlike an average science nerd, AI can explain it simply.
I built OpenScience to make the constant stream of new studies accessible to anyone.
To free science from academic jargon and tiny-fonted PDFs.
OpenScience is a weekly newsletter of 7 compelling studies from the past week in the topic of your choice.
Made simple, digestible, and delightful by AI.
Interested in CRISPR?
The latest Long Covid research?
Psychedelic medicine?
Follow the actual science, as it comes out.
Every study is linked to the original PubMed so you can verify the AI's summary yourself.
Pick a topic, get the weekly email, and give your mind the broccoli it deserves ๐ฅฆ
The real-time unfolding of science is too interesting not to follow.